Products are attained from F. Hoffmann-La Roche and will be exported to more than 90 countries.
Mesekenhagen-based CHEPLAPHARM Arzneimittel GmbH from Mecklenburg-Western Pomerania, Germany, further expands its product portfolio. Just recently, the company attained the rights of two high-revenue products from F. Hoffmann-La Roche. According to CEO Sebastian F. Braun: “With the takeover of VESANOID® and ROHYPNOL® we continue to strengthen our International Footprint and position as a provider of branded niche products.“
With immediate effect, CHEPLAPHARM is the only company in Europe selling the active pharmaceutical ingredient Tretinoin in capsules. VESANOID® contains the ingredient Tretinoin and is applied in the treatment of a special form of leukemia, the Acute Promyelocytic Leukemia (APL) which is a subtype of the Acute Myeloid Leukemia (AML). At the same time, CHEPLAPHARM has taken over the rights for the sedative ROHYPNOL®. Due to the very strict warehouse requirements this product is not stored in the company´s warehouse, but in an external warehouse specialized in narcotics.
The pharmaceuticals ROHYPNOL® and VESANOID® generate a current turnover of 26 million CHF worldwide.
“Due to this decisive expansion of our product portfolio, we are able to drastically progress the internationalization of our business strategy”, says Braun and continues: “CHEPLAPHARM’s share of exports will increase from presently 50 % to more than 75 % in 2013”. The products are marketed in more than 90 countries worldwide.
This is the largest product acquisition since CHEPLAPHARM’s existence. Braun: “By means of this takeover we will nearly double the size of our company. This is a major challenge for the entire team, nevertheless, I am confident that we will manage this demanding project.”
Braun is optimistic that his business can generate a turnover of 44 million EURO within twelve months. Together with subsidiary Walter Ritter GmbH & Co. KG in Hamburg, it may also generate a turnover of 50 million EURO.
Due to the product acquisition, 13 highly qualified jobs are generated at the sites in Mesekenhagen and Greifswald’s business park Ziegelhof. Thus, the number of employees increases to 48.*m/w/d